Kala Pharmaceuticals (NASDAQ:KALA) announced its quarterly earnings data on Thursday. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.01), Fidelity Earnings reports. The business had revenue of $1.45 million during the quarter, compared to analysts’ expectations of $3.56 million.
Shares of KALA stock traded up $0.40 on Friday, hitting $4.11. 374,000 shares of the stock were exchanged, compared to its average volume of 249,192. The firm’s 50 day moving average is $3.84 and its two-hundred day moving average is $5.11. Kala Pharmaceuticals has a one year low of $3.24 and a one year high of $9.25. The firm has a market capitalization of $126.17 million, a PE ratio of -1.66 and a beta of 2.13. The company has a current ratio of 7.50, a quick ratio of 7.04 and a debt-to-equity ratio of 1.16.
KALA has been the subject of a number of recent analyst reports. Wedbush restated an “outperform” rating and issued a $51.00 price objective on shares of Kala Pharmaceuticals in a research note on Wednesday, August 7th. JPMorgan Chase & Co. reduced their price objective on Kala Pharmaceuticals from $22.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday. Zacks Investment Research upgraded Kala Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a research note on Wednesday. Oppenheimer set a $9.00 price objective on Kala Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, HC Wainwright cut their price target on Kala Pharmaceuticals from $15.00 to $12.00 and set a “buy” rating for the company in a research note on Wednesday, August 7th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $17.54.
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Featured Story: Analyzing a company’s cash flow statement
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.